Hosted on MSN11mon
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, PelabresibIn the deal press release, MorphoSys CEO Jean-Paul Kress said, “Pelabresib — the investigational therapy at the forefront of our promising oncology pipeline — has the potential to shift the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback